Pharma major Ranbaxy Laboratories on Thursday said it has scored a legal victory with a United States court ruling that its Cefuroxime Exetil product does not infringe upon the patent rights of GlaxoSmithKline.
Pharma major GlaxoSmithKline Pharmaceuticals Ltd has sold its Worli plot for Rs 107.6 crore (Rs 1.08 billion) to I-Ven Realty Ltd, a joint venture between ICICI Venture Funds Management Company Ltd and Oberoi Constructions.
In spite of a severe second wave of the coronavirus pandemic, and a widespread disruption in public life therefore, India's fast-moving consumer goods (FMGC) sector seems to have emerged as one of the most resilient segments of the economy. The early numbers and estimates for the April-June quarter indicate a steady recovery in FMCG players' business, which is now set to exceed the pre-pandemic level. Amid nationwide lockdowns because of the first Covid wave, FMCG revenues had been severely affected in mid-2020.
Amway surged by converting a multitude into sales agents.
After flirting with 'indulgent' variants, Horlicks and Foodles have tasted success with their health and nutrition positioning.
While Unilever has been aggressive, both organically and inorganically in the country, P&G's approach has been about achieving 'balanced growth' in terms of top line and bottom line.
The British pharma and consumer products maker had announced the open offer in November last year to raise its stake in its subsidiary to 75 per cent from 43.16 per cent at present.
The biggest challenge is crude oil's sustained rally - it is nearing $80 a barrel - stoking inflationary pressures and consequent price hikes in the sector.
147 domestic and international recruiters -- including Ola, Amazon, Flipkart and Xiaomi -- hired all 460 graduates.
Dominant market leader has been adding new users every year, but there are stiff challenges ahead.
The Singapore subsidiary of the UK-based GlaxoSmithKline plans to buy 24.33 per cent stake or 2.06 crore equity shares in GlaxoSmithKline Pharmaceuticals Ltd through an open offer.
Severe price cuts help multinationals ramp up growth, gain market share.
Many are testing hybrid models including getting small batches to work, rotating staff every week, introducing shifts and allowing certain functions to operate from office in small numbers.
GlaxoSmithKline is piggybacking the Rs 1,600-crore (Rs 16-billion) brand to step into newer product categories.
Exports of 13 APIs - including paracetamol, tinidazole, metronidazole, vitamin B1, vitamin B6, vitamin B12, acyclovir, progesterone - along with formulations made from these APIs, would be restricted.
The studies, independently initiated by international non-governmental-organization PATH and Indian Council of Medical Research for GSK and Merck vaccines respectively, were called off early this year after six deaths were reported among the girls who were administered these vaccines in Gujarat and Andhra Pradesh.
By 2022, there is a plan to make an mRNA-technology vaccine, for which it has tied up with Canadian firm Providence Therapeutics.
New variants and innovative product categories on the anvil to beat margin pressure.
Ash content is now allowed up to 1%, the new notification has proposed to increase it to 2% for seasonings or tastemakers.
With the expectation of a big rise in the market for 'sensitive toothpastes' in the near term, GlaxoSmithKline (GSK), the largest company in the health food sector, has forayed into this category in India with its biggest global brand, Sensodyne Toothpaste. This has been launched across all metropolitan and Tier-I cities.
Andrew Witty, chief executive of GlaxoSmithKline (GSK), the world's second-largest drug company, was in India this week as part of the dedication of an albandazole manufacturing facility at Nashik to the World Health Organization (WHO)'s global programme to eliminate Lymphatic Filariasis.
GlaxoSmithKline, the world's second biggest drug maker, said it was interested in acquisitions in India if the assets came at the right value.
US-based Eli Lilly has planned to continue its focus on innovation-driven products, instead of opening up to opportunities in off-patent generic drugs, being tapped by its larger competitors like GSK and Pfizer.
Bubbly is the latest in a string of brands that are touching the three-digit mark quickly.
IT sector's trading multiples hit post-Lehman lows, providing good entry points.
Dr Reddy's has reached an out-of-court settlement to launch the Glaxo-patented Imitrex, a migraine drug that had annual sales of $878 million as of March 31, 2006, in the US. Experts estimate Dr Reddy's may not get more than $8-$15 million sales in 2009 since majority of sales revenue has to be given to GSK, for allowing the launch the authorised generic version.
ITC has provided retailers with leaflets to assure customers of Yippee noodle's quality and safety standards
GSK India, which has a turnover of Rs 1,751 crore (Rs 17.51 billion) and launched a cervical cancer drug, Cervarix, and breast cancer drug, Tykerb, last year, plans to launch Promacta, the first oral medication to increase platelet production for people with serious blood disorder, from its parent stable during the current year. Promacta is a relatively new drug, for which approval was given by the US Food and Drug Administration in November last year.
Drug major Ranbaxy Laboratories could suffer a potential revenue loss to the tune of Rs 300 crore (Rs 3 billion) due to delay in receiving approval from the US Food and Drug Administration (FDA) for generic version of GSK's anti-migraine medicine Imitrex, according to analysts.
A glance back at some of the important ups and down Indian Inc faced in 2018.
The markets opened in green tracking its Asian peers
A large number of American companies like Google, Uber and IBM are offering their resources to help India successfully fight the battle against the deadly coronavirus pandemic.
Some investment bankers expect the Indian currency to touch 60-65 by the end of the year
The much-awaited merger of Burroughs Wellcome India Ltd with GlaxoSmithKline Pharmaceuticals Ltd in the country was approved by boards of both entities on Wednesday with a swap ratio of 14:10 shares.
© 2026 Rediff.com - Investor Information - Advertise with us - Disclaimer - Privacy Policy - Sitemap - Feedback - About us - Terms of use - Grievances